News | Cath Lab | April 17, 2017

Study Finds Significant Variability in Doctors' Angioplasty Death Rates

Judging doctors on mortality data may not give the full picture

Study Finds Significant Variability in Doctors Angioplasty Death Rates

April 17, 2017 — Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI). However, doctors should not be judged solely on the rate of patients who die from the procedure, as the rate is highly variable over time, according to a recent study in JACC: Cardiovascular Interventions

PCI is a nonsurgical procedure that improves blood flow to the heart. It requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye into the coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.

The new study analyzed data from the National Cardiovascular Data Registry CathPCI Registry to determine how many physicians had mortality rates outside the expected norm. The study included 3,760 doctors who performed 2,343,693 PCI procedures. The researchers adjusted for a number of factors, including how sick patients were.

The researchers found a small but significant number of doctors (6.5 percent) with mortality rates above what would be expected, as well as a small but significant number (4.1 percent) with mortality rates below what would be expected.

PCI mortality rates for individual doctors may be useful for both doctors and hospitals to assess and monitor their care and see where they need improvement, said Jacob Doll, M.D., a cardiologist at the University of Washington in Seattle and lead author of the study. “It could drive hospitals and doctors to further improve the safety of a procedure that’s already low-risk. However, I don’t see this measure as ready for widespread use as a publicly reported measure or to influence payment.”

A limitation with assessing mortality rates is that it is rare for patients to die from PCI — for every 100 procedures, only slightly more than 1 percent of patients die, and for elective PCI, death is very rare.

“Any given doctor may have only one or two deaths a year — some years just by chance you may have two or four, which seems like a lot, and the next year, you may have none. This may be further confounded by the low number of deaths that can be ascribed to the procedure, and makes it challenging to know whether these differences are actually due to the care received,” Doll said.

A number of factors affect a physician’s PCI mortality rate, Doll said. 

Because procedures performed on sicker patients often have higher mortality rates, Doll and colleagues took this into account, by using what is called a risk standardized mortality rate (RSMR).

“This helps us interpret the results to determine who really has a higher-than-expected morality rate, and who has a higher actual mortality rate because they take care of sicker patients,” he said.

In an editorial accompanying the study, Michael McDaniel, M.D., an assistant professor of medicine at Emory University School of Medicine in Atlanta, said that doctors concerned about their mortality rate being reported publicly may avoid treating the highest-risk patients.


Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Better Prognosis for Some PCI Patients When Operators Perform More Procedures


For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init